Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Saluja Kaduwal 1, 2 , Woo-Jeong Jeong 1, 2 , Jong-Chan Park 1, 2 , Kug Hwa Lee 1, 2 , Young-Mi Lee 1, 2, 5 , Soung-Hoo Jeon 1, 2, 6 , Yong-Beom Lim 1, 3 , Do Sik Min 1, 4 , Kang-Yell Choi 1, 2 1 Translational Research Center for Protein Function Control, Yonsei University, Seoul, 120-749, Korea 2 Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 120-749, Korea 3 Department of Materials Science and Engineering, Yonsei University, Seoul, 120-749, Korea 4 Department of Molecular Biology, College of Natural Science, Pusan National University, Pusan, 609-735, Korea 5 Current address: Division of Pharmacology and Translational Research, Hanmi Research Center, Hwaseong-si Gyeonggi-do, 445-813, Korea 6 Current address: Department of Microbiology and Immunology, Xenotransplantation Research Center, Medical Research Center, Institute of Endemic Disease, Seoul National University College of Medicine, Seoul, 110-799, Korea Correspondence to: Kang-Yell Choi, e-mail: kychoi@yonsei.ac.kr Keywords: Sur8, Ras, PI3K, cell migration, metastasis Received: June 02, 2015 Accepted: August 26, 2015 Published: September 05, 2015 ABSTRACT Sur8 (also known as Shoc2) is a Ras-Raf scaffold protein that modulates signaling through extracellular signal-regulated kinase (ERK) pathway. Although Sur8 has been shown to be a scaffold protein of the Ras-ERK pathway, its interaction with other signaling pathways and its involvement in tumor malignancy has not been reported. We identified that Sur8 interacts with the p110α subunit of phosphatidylinositol 3-kinase (PI3K), as well as with Ras and Raf, and these interactions are increased in an epidermal growth factor (EGF)- and oncogenic Ras-dependent manner. Sur8 regulates cell migration and invasion via activation of Rac and matrix metalloproteinases (MMPs). Interestingly, using inhibitors of MEK and PI3K we found Sur8 mediates these cellular behaviors predominantly through PI3K pathway. We further found that human metastatic melanoma tissues had higher Sur8 content followed by activations of Akt, ERK, and Rac. Lentivirus-mediated Sur8-knockdown attenuated metastatic potential of highly invasive B16-F10 melanoma cells indicating the role of Sur8 in melanoma metastasis. This is the first report to identify the role of scaffold protein Sur8 in regulating cell motility, invasion, and metastasis through activation of both ERK and PI3K pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“In addition, oncogenic Ras-driven tumor malignancy is observed in one-third of all human cancers [35, 36], Ras has become a major target for the development of anti-cancer drugs.”
BackgroundHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762 · cited 2×
“The activated Ras-Raf-ERK cascade is implicated in the activation of various target genes controlling cellular proliferation, differentiation, and transformation [3], as well as cell motility [4, 5].”
BackgroundResultRodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., & McCormick, F. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.027 · Cited by 215 · cited 1×
“However, other studies have reported Sur8 interacts only with M-Ras but not with other isoforms of Ras to regulate ERK pathway [16, 17].”
Background
Cited by
Functional dysregulation of CDC42 causes diverse developmental phenotypes
Martinelli, S., Krumbach, O. H. F., Pantaleoni, F., Coppola, S., Amin, E., Pannone, L., Nouri, K., Farina, L., Dvorsky, R., Lepri, F., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.12.015 · Cited by 188
Xie, C.-M., Tan, M., Lin, X.-T., Wu, D., Jiang, Y., Tan, Y., Li, H., Ma, Y., Xiong, X., & Sun, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.052 · Cited by 49
Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Self-citation
Metadata
- Authors
- Kaduwal, S., Jeong, W.-J., Park, J.-C., Lee, K. H., Lee, Y.-M., Jeon, S.-H., Lim, Y.-B., Min, D. S., & Choi, K.-Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-05
- Volume
- 6
- Issue
- 32
- Pages
- 33091-33105
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2226889062
- Cited by
- 40
- References
- 5
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.